Trial · NCT02879747

Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children

NCT02879747, Phase 2, Phase 3, Completed, Göteborg University; results first posted 2019-04-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children. Trials, record NCT02879747. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02879747

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children
NCT number: NCT02879747
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 99 participants, actual
Lead sponsor: Göteborg University
Conditions: Short Stature
Interventions: Genotropin
First posted: 2016-08-26
Last updated: 2019-04-30
Results first posted: 2019-04-30

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Proportion of Children Maintaining Normal Growth Velocity	twelve months	The proportion of children in the intervention 1 group (=reduced dose) that maintained an individual ΔheightSDS within ±0.3 during the first year of the Maintenance trial, compared to the proportion of children in the intervention 2 group (non-reduced dose)
Secondary	IGF-I	start of study to two years after start in the trial	Delta Insulin-like growth factor-I (24 months after start compared to start of study) expressed as ng/ml and converted to standard deviation scores (SDS) to adjust for gender and age. A standard deviation score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A mean value within +-0.5 SDS and a range within +-1.0 SDS is a favorable outcome.
Secondary	Height SDS at Start of Puberty	1-7 years in the trial	Height at start of puberty measured as cm and expressed as standard deviation score (SDS) to adjust for age and gender
Other	Changes in Height	start of study to two years after start in the trial	Changes in height standard deviation scores (SDS) (calculated as height in cm at start converted to SDS and height in cm after two years in the trial converted to SDS)

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Proportion of Children Maintaining Normal Growth Velocity	twelve months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	IGF-I	start of study to two years after start in the trial	Drop outs due to puberty or adverse events	standard deviation scores	MEAN
SECONDARY	Height SDS at Start of Puberty	1-7 years in the trial	All 98 Children were measured at start of puberty	standard deviation scores	MEAN
OTHER_PRE_SPECIFIED	Changes in Height	start of study to two years after start in the trial		standard deviation scores	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
The Proportion of Children Maintaining Normal Growth Velocity	Decreased GH Dose	23		Participants
The Proportion of Children Maintaining Normal Growth Velocity	Interventional 2	32		Participants
The Proportion of Children Maintaining Normal Growth Velocity	Control Group	31		Participants
IGF-I	Unchanged Dose	-1.10	Standard Deviation 1.14	standard deviation scores
IGF-I	Reduced Dose	0.58	Standard Deviation 0.91	standard deviation scores
IGF-I	Control Group	-0.06	Standard Deviation 1.26	standard deviation scores
Height SDS at Start of Puberty	Decreased GH Dose	-1.0	Standard Deviation 1.02	standard deviation scores
Height SDS at Start of Puberty	Unchanged GH Dose	-1.06	Standard Deviation 0.84	standard deviation scores
Height SDS at Start of Puberty	Control Group	-0.98	Standard Deviation 0.91	standard deviation scores
Changes in Height	Unchanged Dose	0.18	Standard Deviation 0.16	standard deviation scores

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Decreased GH Dose	27
Overall Study	STARTED	Unchanged GH Dose	38
Overall Study	STARTED	Control Group	33
Overall Study	COMPLETED	Decreased GH Dose	23
Overall Study	COMPLETED	Unchanged GH Dose	32
Overall Study	COMPLETED	Control Group	31
Overall Study	NOT COMPLETED	Decreased GH Dose	4
Overall Study	NOT COMPLETED	Unchanged GH Dose	6
Overall Study	NOT COMPLETED	Control Group	2

Source ClinicalTrials.gov

Adverse events21

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	virosis	Infections and infestations	Decreased GH Dose	20	27	52
other	virosis	Infections and infestations	Unchanged GH Dose	25	38	46
other	virosis	Infections and infestations	Control Group	24	33	53
serious	Otitis media	Ear and labyrinth disorders	Decreased GH Dose	1	27	1
serious	Otitis media	Ear and labyrinth disorders	Unchanged GH Dose	0	38	0
serious	Otitis media	Ear and labyrinth disorders	Control Group	0	33	0
serious	Abdominal pain	Gastrointestinal disorders	Decreased GH Dose	1	27	1
serious	Abdominal pain	Gastrointestinal disorders	Unchanged GH Dose	1	38	1
serious	Abdominal pain	Gastrointestinal disorders	Control Group	0	33	0
serious	facial nerve palsy due to tick disease	Infections and infestations	Decreased GH Dose	1	27	1

1 to 10 of 21Source ClinicalTrials.gov

See all 21 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Decreased GH Dose	0	27
Total, all-cause mortality	Unchanged GH Dose	0	38
Total, all-cause mortality	Control Group	0	33
Total, other adverse events	Decreased GH Dose	20	27
Total, other adverse events	Unchanged GH Dose	25	38
Total, other adverse events	Control Group	24	33
Total, serious adverse events	Decreased GH Dose	3	27
Total, serious adverse events	Unchanged GH Dose	4	38
Total, serious adverse events	Control Group	3	33

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
11004238	BACKGROUND	PubMed
19001519	RESULT	PubMed
30339244	DERIVED	PubMed
39906034	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02879747

GET https://conductscience.org/api/trials/v1/NCT02879747/events?page=2

API reference For AI assistants